On January 14, 2026, ModuleMD Healthcare Solutions released a comprehensive, claims-based analysis titled The Changing Economics of Allergy Care: A Data-Driven Reimbursement Review. Drawing from more than 10 million Allergy & Immunology claims processed between 2021 and 2025, the report paints a sobering – yet actionable – picture of the financial realities facing allergy practices in the United States.
Key Findings – The Old Model Is Breaking
- Reimbursements Are Falling Behind Inflation
Core allergy procedures (skin testing, allergen immunotherapy extract preparation, pulmonary function testing) have seen near-zero or negative real reimbursement growth over the five-year period.
When adjusted for general healthcare inflation, many of these services would be worth 12–15 % more today if rates had simply kept pace. Instead, practices are delivering the same (or more complex) care for effectively less money each year. - Biologics & Infusions Now Drive 25–35 % (and Up to 50 %) of Total Collections
In-office administration of biologics (omalizumab/Xolair, dupilumab/Dupixent, mepolizumab/Nucala, benralizumab/Fasenra, tezepelumab/Tezspire etc.) has become the dominant revenue engine for high-performing practices.
The share of total collections coming from these high-value services has nearly doubled since 2021. Some mature practices now derive more than half of their revenue from biologic infusions alone. - Geography & Payer Mix Create Extreme Variability
The same CPT code can reimburse up to 2× more depending on the region and the specific payer contracts.
Practices with a highly concentrated payer mix (one or two carriers >70 % of revenue) show significantly higher denial rates, lower clean-claim percentages, and much greater financial volatility. - Top Performers Are 22 % Ahead on Revenue per Provider
Practices that actively manage their service mix, diversify payers, automate prior authorizations and benefit investigations, and use real-time reimbursement analytics consistently outperform peers by approximately 22 % in revenue per full-time equivalent provider.
Why This Shift Is Structural – Not Cyclical
The report identifies several irreversible forces reshaping allergy economics:
- Flat or declining reimbursements for traditional services (skin testing, immunotherapy vials, spirometry) despite rising costs for staff, rent, supplies, and liability insurance
- Rapid adoption of biologics that require complex authorization workflows, inventory management, buy-and-bill risk, and payer-specific medical necessity documentation
- Increasing payer scrutiny (step therapy, white bagging, site-of-care restrictions) that adds administrative burden without additional compensation
- Growing biosimilar competition (especially for omalizumab) that will likely compress biologic margins in the coming 24–36 months
What the Most Successful Practices Are Doing Right Now (2026 Best Practices)
According to ModuleMD’s analysis, leading allergy groups share several common strategies:
- Aggressive payer diversification – actively contracting with regional and national plans to avoid over-reliance on any single carrier
- In-house or outsourced biologic authorization & billing teams – turning prior authorizations from a bottleneck into a competitive advantage
- AI-enabled revenue cycle workflows – using artificial intelligence to predict denial risk, auto-generate appeals, and optimize billing modifiers
- Service-mix optimization – deliberately shifting capacity toward high-value biologic patients while maintaining a sustainable base of traditional services
- Real-time reimbursement dashboards – tracking payment variance by payer, CPT, and geography weekly instead of monthly or quarterly
Bottom Line for Allergy Practice Leaders in 2026
The era of “see more patients, make more money” is over in allergy & immunology. The practices that thrive over the next decade will be defined by:
- How intelligently they manage their revenue mix (traditional vs. high-value biologic services)
- How effectively they diversify and negotiate with payers
- How aggressively they automate and use data to protect margins
- How quickly they adapt to biosimilars and site-of-care restrictions
Volume still matters – but data, diversification, and operational intelligence matter more.
The full 50+ page report (including detailed benchmarks, regional reimbursement maps, payer-specific denial patterns, and actionable checklists) is freely available for download:
? The Changing Economics of Allergy Care: A Data-Driven Reimbursement Review
